Skip to content

Special populations

TL;DR — GAD's evidence base is built on working-age adults, and the three populations that fall outside it each behave differently. Children and adolescents: escitalopram beat placebo in a 275-patient multicentre trial (PARS-GAD LS mean difference −1.42, p=0.028), extending efficacy down to age 7 (Strawn 2023, PMID 37074330); in the landmark CAMS trial (n=488, ages 7–17, GAD/separation anxiety/social phobia), response was 80.7% for sertraline+CBT, 59.7% CBT, 54.9% sertraline, 23.7% placebo, with combination superior to both monotherapies (Walkup 2008, PMID 18974308, NCT00052078). Older adults: escitalopram's benefit in 177 adults ≥60 was significant in the primary censored analysis (69% vs 51% cumulative response, p=0.03) but not in the conservative intention-to-treat analysis (57% vs 45%, p=0.11) (Lenze 2009, PMID 19155456); CBT's effect is moderate in older adults (g=0.55, 95% CI 0.22–0.88) versus large in working-age adults (g=0.94, 0.52–1.36), a difference driven partly by the fact that no older-adult study used intention-to-treat (Kishita 2017, PMID 28119196). The USPSTF issued an "insufficient evidence" statement for screening adults ≥65 (USPSTF 2023, PMID 37338866), drawing a published objection (Andreescu 2023, PMID 36652241). Perinatal: 4.1% (95% CI 1.9–6.2) of pregnant and 5.7% (2.3–9.2) of postpartum women meet criteria for GAD specifically, against 15.2% and 9.9% for any anxiety disorder (Dennis 2017, PMID 28302701); CBT is effective for perinatal anxiety short- and long-term (SMD −0.63 and −0.71) (Li 2022, PMID 35123346).

Children and adolescents

Trial / analysis Design Result
CAMS (Walkup 2008, PMID 18974308, NCT00052078) 488 children aged 7–17, primary separation anxiety, GAD or social phobia; CBT (14 sessions) vs sertraline ≤200 mg vs combination vs placebo, 12 weeks, 2:2:2:1 CGI-I much/very much improved: combination 80.7%, CBT 59.7%, sertraline 54.9%, placebo 23.7%; all superior to placebo (p<0.001); combination superior to both monotherapies; no suicide attempts; suicidal/homicidal ideation no more frequent on sertraline than placebo; less insomnia, fatigue, sedation and restlessness with CBT
Strawn 2020 (PMID 32857933, NCT02818751) 51 adolescents with DSM-IV-TR GAD; escitalopram 15→20 mg vs placebo, 8 weeks PARS change −8.65±1.3 vs −3.52±1.1 (p=0.005); CGI also superior; CYP2C19 metabolism significantly affected escitalopram exposure (AUC₀₋₂₄ p<0.05), raising a pharmacogenetic dosing question
Strawn 2023 (PMID 37074330, NCT03924323) 275 children/adolescents aged 7–17 with primary GAD; flexible escitalopram 10–20 mg vs placebo, 8 weeks PARS-GAD LS mean difference −1.42 (p=0.028); CGAS functional improvement numerically greater but not significant (p=0.286); AE discontinuation not different; extends safety data to ages 7–11
Wang 2017 (PMID 28859190) Systematic review/meta-analysis, 115 studies, 7,719 patients, mean age 9.2 years — pooled across childhood anxiety disorders SSRIs vs pill placebo: remission RR 2.04 (1.37–3.04), response RR 1.96 (1.60–2.40); SNRIs reduced clinician-rated symptoms; benzodiazepines and tricyclics did not; CBT beat waitlist/no treatment; CBT reduced symptoms more than fluoxetine and improved remission more than sertraline; sertraline+CBT beat either alone; head-to-head comparisons sparse
Mohammadi 2020 (PMID 32470794) 29,709 Iranian children/adolescents 6–18, K-SADS-PL Lifetime GAD 2.6% (95% CI 2.4–2.8); 57.6% comorbid with another anxiety disorder; predictors: age, sex, maternal psychiatric hospitalisation, maternal education, residence
USPSTF 2022 (PMID 36219403) Recommendation statement Screen ages 8–18 (B); insufficient evidence ≤7 years; 7.8% of 3–17-year-olds had a current anxiety disorder in the 2018–2019 National Survey of Children's Health
Tolin 2023 (PMID 36632642) DIAMOND-KID structured interview, 311 patients aged 10–17 Inter-rater reliability questionable specifically for GAD and MDD, good-to-very-good for other diagnoses

Two GAD-specific points. The CAMS result — combination > monotherapy, and CBT ≈ sertraline — is the strongest comparative-effectiveness evidence in the whole GAD lifespan literature, but it pooled three anxiety disorders (Walkup 2008, PMID 18974308). And Wang 2017's finding that benzodiazepines and tricyclics do not reduce childhood anxiety (PMID 28859190) is a rare unambiguous negative in a literature dominated by small positives. Antidepressant adverse effects and deprescribing in this age group have their own literatures (Strawn 2023, PMID 36651686; Stimpfl 2025, PMID 39469761), and the pediatric antidepressant–suicidality signal is the standing safety context (Hammad 2006, PMID 16520440) — see red flags and safety concerns.

What happens to treated children years later — the CAMELS follow-ups

CAMS (Walkup 2008, PMID 18974308) is the only GAD-relevant paediatric trial with a long-term naturalistic follow-up programme, and its results reframe the acute-response numbers.

Follow-up Sample Result
Ginsburg 2014 (PMID 24477837) 288 of the 488 CAMS youths (59.0%), assessed a mean of 6 years after randomisation at 6 academic sites 46.5% in remission (absence of all study-entry anxiety disorders). Acute treatment responders were significantly more likely to be in remission (OR 1.83, 1.08–3.09) with less severe symptoms and better functioning; assigned treatment did not predict remission
Ginsburg 2018 (PMID 29960692) 319 youths, annual assessment across a 4-year window beginning 4–12 years after randomisation; remission defined rigorously as absence of all anxiety disorders across all follow-up years 21.7% stably remitted, 30% chronically ill, 48% relapsers. Acute responders were less likely to be chronically ill (OR 2.73, 1.14–6.54, p<0.02); treatment type again did not predict remission status
Swan 2018 (PMID 30138013) 319 families, growth-curve modelling of functioning 3–12 years post-randomisation Responders and remitters had better global functioning, less impairment and higher life satisfaction. CBT (vs pill placebo) improved trajectories for life satisfaction, overall impairment and academic impairment; sertraline's trajectory did not differ from placebo. Randomisation to CBT or combination was associated with increasing employment rates
Cochrane (James 2015, PMID 25692403) RCTs of CBT vs waitlist, active controls, TAU or medication in childhood/adolescent anxiety (excluding simple phobia, OCD, PTSD, selective mutism) The reference synthesis of paediatric CBT

Three things follow. Acute response predicted later remission, while assigned treatment did not predict remission in CAMELS; this does not establish that modality is irrelevant to every outcome. Roughly half relapsed, and under a strict definition about one in five achieved stable remission across years. On some long-term functional outcomes, CBT separated from placebo where sertraline did not (Swan 2018, PMID 30138013), despite similar acute response rates for sertraline (54.9%) and CBT (59.7%) (Walkup 2008, PMID 18974308). Short acute trials do not capture either distinction.

Older adults

Question Evidence Answer
How common is late-life GAD? NESARC-2, 12,312 adults ≥55 Past-year 2.80%; only 0.53% without any Axis I or II comorbidity; help-seeking 18% (no comorbidity) / 28.3% (with) (Mackenzie 2011, PMID 21427639)
Does an SSRI work? 177 adults ≥60, escitalopram 10–20 mg vs placebo, 12 weeks Primary (censored-at-dropout) cumulative response 69% (58–80) vs 51% (40–62), p=0.03; conservative ITT 57% vs 45%, p=0.11; CGI-I effect size 0.93 (0.50–1.36); PSWQ 0.30 (0.23–0.48) (Lenze 2009, PMID 19155456)
Do antidepressants work generally? 10 RCTs across 12 papers in late-life anxiety Significant reduction in anxiety symptoms, generally well tolerated; preponderance of GAD, limited long-term data (Balasubramaniam 2019, PMID 31369663)
Does CBT work? 14 RCTs, N=985, PSWQ/PSWQ-A required Superior to waitlist/TAU at post-treatment and 6 months; small non-significant advantage over active controls at post-treatment, equivalent at follow-up (Hall 2016, PMID 27687212)
Is CBT as good as in younger adults? 15 studies, 22 comparisons, 770 patients No statistically significant age-group difference, but g=0.55 (0.22–0.88) older vs g=0.94 (0.52–1.36) working-age; no older-adult study used an ITT design; protocols were robust CBT but not adapted to gerontological evidence (Kishita 2017, PMID 28119196)
Does CBT work in primary care for older adults? 134 older adults (mean age 66.9) in two primary-care settings randomised to 3 months of CBT (n=70) or enhanced usual care (n=64), followed to 15 months. CBT improved worry severity (PSWQ 45.6 vs 54.4, p<0.001), depressive symptoms (BDI-II 10.2 vs 12.8, p=0.02) and general mental health (SF-12 49.6 vs 45.3, p=0.008) — but showed no difference on GAD severity (8.6 vs 9.9, p=0.19), the trial's co-primary outcome (Stanley 2009, PMID 19351943) Efficacy is outcome-dependent
Is ACT feasible? 16 older primary-care patients (Wetherell 2011, PMID 21292059); FACTOID feasibility programme in treatment-resistant late-life GAD (Gould 2021, PMID 34542399) Feasible; efficacy untested at scale
What is the recommended sequence? Harvard South Shore algorithm SSRI (sertraline/escitalopram) → different SSRI or venlafaxine/duloxetine → pregabalin/gabapentin, lavender oil, agomelatine → quetiapine; caution with benzodiazepines and hydroxyzine; note that many older patients were started on benzodiazepines decades earlier and need periodic benefit–harm review (Chen 2025, PMID 39352792)
Should we screen? USPSTF 2023 I statement — insufficient evidence in adults ≥65 (PMID 37338866); contested as an artefact of under-study rather than absence of benefit (Andreescu 2023, PMID 36652241)
Does presentation differ? 375 clinical participants matched on GAD status and severity Differential item functioning: older adults higher on distress/interference, lower on fatigue, at equal latent severity; more worry about world affairs and own health, less about work/school (Correa 2019, PMID 31938010)
Cognitive consequences? Late-life GAD vs comparison Cognitive impairment documented in late-life GAD (Mantella 2007, PMID 17426260)

The recurring methodological problem in late-life GAD is analysis convention, not effect size: escitalopram's benefit survives one analysis and not another (Lenze 2009, PMID 19155456), and CBT's smaller effect in older adults is confounded by universal absence of ITT designs (Kishita 2017, PMID 28119196). Neither finding licenses the conclusion that treatment works less well in older adults; both license the conclusion that it has been studied less well.

Perinatal

Metric Value Source
Self-reported anxiety symptoms, first / second / third trimester 18.2% (13.6–22.8) / 19.1% (15.9–22.4) / 24.6% (21.2–28.0) Dennis 2017, PMID 28302701 (102 studies, 221,974 women, 34 countries)
Any anxiety disorder, antenatal (clinical diagnosis) 15.2% (9.0–21.4) Dennis 2017, PMID 28302701
GAD specifically, antenatal 4.1% (1.9–6.2) Dennis 2017, PMID 28302701
Any anxiety disorder, postnatal (1–24 weeks) 9.9% (6.1–13.8); symptoms 15.0% (13.7–16.4) Dennis 2017, PMID 28302701
GAD specifically, postnatal 5.7% (2.3–9.2) Dennis 2017, PMID 28302701
Comorbid anxiety and depression, perinatal ~9% (8–10%); pregnancy 9% (8–11), postpartum 8% (7–10); 122 articles, 560,736 women, 43 countries Ou 2025, PMID 40079080
Both parents Perinatal depression and anxiety prevalence estimated in mothers and fathers Smythe 2022, PMID 35749112
CBT for perinatal anxiety Short-term SMD −0.63 (−0.85 to −0.42); long-term −0.71 (−1.02 to −0.39); 79 RCTs/quasi-RCTs Li 2022, PMID 35123346
Screening accuracy in pregnancy Systematic review and meta-analysis of test accuracy for identifying depression and anxiety during pregnancy Rondung 2024, PMID 38014572
Screening policy USPSTF recommends screening adults including pregnant and postpartum persons (B) USPSTF 2023, PMID 37338866
Clinical approach Perinatal anxiety: diagnosis and management in the obstetric setting Thorsness 2018, PMID 29803818
Trajectories Prevalence and trajectories of perinatal anxiety and depression in a large urban medical centre Solomonov 2025, PMID 40982279

Note the gap between symptom-scale and disorder-level estimates in pregnancy: 24.6% report third-trimester anxiety symptoms against 4.1% meeting GAD criteria (Dennis 2017, PMID 28302701). The 2020 Women's Preventive Services Initiative review identified no treatment trials in pregnant or postpartum women (Nelson 2020, PMID 32510989). A later cluster-RCT secondary analysis compared two systems-level perinatal programmes among depression-screen-positive participants and measured GAD symptoms (Zimmermann 2024, PMID 38992743), so a blanket “no treatment trial” claim is now stale. A targeted PubMed search on 2026-09-02 still found no perinatal GAD pharmacotherapy RCT.

Other populations touched by this literature

  • University students: 57.4% of 72,288 first-year students across 18 countries screened positive for any 12-month disorder; internalizing disorders more prevalent in females and among non-heterosexual and transgender students; weighted response rate 20.8% (Mason 2025, PMID 40010072). Childhood adversity carried population attributable risk proportions of 40.7–61.0% for 12-month anxiety and mood disorders in the same programme (Husky 2025, PMID 40541041).
  • Veterans: probable GAD 7.9% (6.7–9.3) and mild anxiety symptoms 22.1% (20.5–23.9) in a nationally representative US sample, with a dose–response relation to suicidal thoughts and functional impairment (Macdonald-Gagnon 2024, PMID 38325107). Screener-based; overlaps heavily with PTSD.

Open questions

  • Does escitalopram work in older adults with GAD? The answer differs by analysis convention within a single trial (Lenze 2009, PMID 19155456). A targeted PubMed search rerun on 2026-09-02 located no adequately powered conservative-ITT replication; this remains a dated replication gap.
  • Would age-adapted CBT close the g=0.55 vs 0.94 gap (Kishita 2017, PMID 28119196)? The content analysis found protocols were robust but not gerontologically adapted — a directly testable hypothesis.
  • Why does acute treatment response predict long-term remission while assigned treatment did not predict remission (Ginsburg 2014, PMID 24477837; Ginsburg 2018, PMID 29960692)? Because CBT did predict some functional trajectories (Swan 2018, PMID 30138013), the next question is how early response and modality jointly shape remission and function—not whether modalities are interchangeable.
  • Should CYP2C19 phenotype guide escitalopram dosing in adolescents (Strawn 2020, PMID 32857933)? The pharmacokinetic signal is clear; the clinical trial is not done.
  • Why is GAD's inter-rater reliability "questionable" in children (Tolin 2023, PMID 36632642) — the same weak point as in adults (diagnosis and classification)?
  • What is safe and effective pharmacotherapy for GAD in pregnancy? The WPSI review found no treatment trials through its search period (Nelson 2020, PMID 32510989), and a targeted PubMed search rerun on 2026-09-02 found no perinatal GAD pharmacotherapy RCT. Systems-level symptom evidence does now exist (Zimmermann 2024, PMID 38992743).
  • Why did primary-care CBT in older adults improve worry, depression and mental-health quality of life but not GAD severity (Stanley 2009, PMID 19351943)? The dissociation between worry and GAD-severity outcomes recurs across the late-life literature.
  • Is late-life GAD under-studied or genuinely different? The USPSTF I statement and its published rebuttal frame this exactly (USPSTF 2023, PMID 37338866; Andreescu 2023, PMID 36652241).

References

  1. Walkup JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359:2753-66. PMID 18974308
  2. Strawn JR, et al. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2020;81:20m13396 (online). PMID 32857933
  3. Strawn JR, et al. A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder. J Child Adolesc Psychopharmacol. 2023;33:91-100. PMID 37074330
  4. Wang Z, et al. Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis. JAMA Pediatr. 2017;171:1049-1056. PMID 28859190
  5. Mohammadi MR, et al. Generalized anxiety disorder: Prevalence, predictors, and comorbidity in children and adolescents. J Anxiety Disord. 2020;73:102234. PMID 32470794
  6. US Preventive Services Task Force. Screening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328:1438-1444. PMID 36219403
  7. Tolin DF, et al. The DIAMOND-KID: Psychometric Properties of a Structured Diagnostic Interview for DSM-5 Anxiety, Mood, and Obsessive-Compulsive and Related Disorders in Children and Adolescents. Assessment. 2023;30:2351-2363. PMID 36632642
  8. Strawn JR, et al. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy. 2023;43:675-690. PMID 36651686
  9. Stimpfl JN, et al. Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms. J Child Adolesc Psychopharmacol. 2025;35:3-22. PMID 39469761
  10. Hammad TA, et al. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332-9. PMID 16520440
  11. Mackenzie CS, et al. Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. Am J Geriatr Psychiatry. 2011;19:305-15. PMID 21427639
  12. Lenze EJ, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA. 2009;301:295-303. PMID 19155456
  13. Balasubramaniam M, et al. Antidepressants for anxiety disorders in late-life: A systematic review. Ann Clin Psychiatry. 2019;31:277-291. PMID 31369663
  14. Hall J, et al. Efficacy of Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults: Systematic Review, Meta-Analysis, and Meta-Regression. Am J Geriatr Psychiatry. 2016;24:1063-1073. PMID 27687212
  15. Kishita N, Laidlaw K. Cognitive behaviour therapy for generalized anxiety disorder: Is CBT equally efficacious in adults of working age and older adults? Clin Psychol Rev. 2017;52:124-136. PMID 28119196
  16. Wetherell JL, et al. Acceptance and Commitment Therapy for generalized anxiety disorder in older adults: a preliminary report. Behav Ther. 2011;42:127-34. PMID 21292059
  17. Gould RL, et al. Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: the FACTOID feasibility study. Health Technol Assess. 2021;25:1-150. PMID 34542399
  18. Chen A, et al. A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient. J Geriatr Psychiatry Neurol. 2025;38:155-171. PMID 39352792
  19. US Preventive Services Task Force. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329:2163-2170. PMID 37338866
  20. Andreescu C, et al. Is Anxiety in Late Life an Uncharted Territory? JAMA Psychiatry. 2023;80:197-198. PMID 36652241
  21. Correa JK, Brown TA. Expression of Generalized Anxiety Disorder Across the Lifespan. J Psychopathol Behav Assess. 2019;41:53-59. PMID 31938010
  22. Mantella RC, et al. Cognitive impairment in late-life generalized anxiety disorder. Am J Geriatr Psychiatry. 2007;15:673-9. PMID 17426260
  23. Dennis CL, et al. Prevalence of antenatal and postnatal anxiety: systematic review and meta-analysis. Br J Psychiatry. 2017;210:315-323. PMID 28302701
  24. Ou L, et al. Prevalence of co-morbid anxiety and depression in pregnancy and postpartum: a systematic review and meta-analysis. Psychol Med. 2025;55:e84. PMID 40079080
  25. Smythe KL, et al. Prevalence of Perinatal Depression and Anxiety in Both Parents: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5:e2218969. PMID 35749112
  26. Li X, et al. Effectiveness of cognitive behavioral therapy for perinatal maternal depression, anxiety and stress: A systematic review and meta-analysis of randomized controlled trials. Clin Psychol Rev. 2022;92:102129. PMID 35123346
  27. Rondung E, et al. Identification of depression and anxiety during pregnancy: A systematic review and meta-analysis of test accuracy. Acta Obstet Gynecol Scand. 2024;103:423-436. PMID 38014572
  28. Thorsness KR, et al. Perinatal anxiety: approach to diagnosis and management in the obstetric setting. Am J Obstet Gynecol. 2018;219:326-345. PMID 29803818
  29. Solomonov N, et al. Prevalence and Trajectories of Perinatal Anxiety and Depression in a Large Urban Medical Center. JAMA Netw Open. 2025;8:e2533111. PMID 40982279
  30. Nelson HD, et al. Screening for Anxiety in Adolescent and Adult Women: A Systematic Review for the Women's Preventive Services Initiative. Ann Intern Med. 2020;173:29-41. PMID 32510989
  31. Mason A, et al. Prevalence, age-of-onset, and course of mental disorders among 72,288 first-year university students from 18 countries. J Psychiatr Res. 2025;183:225-236. PMID 40010072
  32. Husky MM, et al. Childhood adversities and their associations with mental disorders in the World Mental Health International College Student surveys initiative. Psychiatry Res. 2025;351:116585. PMID 40541041
  33. Macdonald-Gagnon G, et al. Generalized anxiety and mild anxiety symptoms in U.S. military veterans. J Psychiatr Res. 2024;171:263-270. PMID 38325107
  34. Ginsburg GS, et al. Naturalistic follow-up of youths treated for pediatric anxiety disorders. JAMA Psychiatry. 2014;71:310-8. PMID 24477837
  35. Ginsburg GS, et al. Results From the Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes. J Am Acad Child Adolesc Psychiatry. 2018;57:471-480. PMID 29960692
  36. Swan AJ, et al. Results from the Child/Adolescent Anxiety Multimodal Longitudinal Study (CAMELS): Functional outcomes. J Consult Clin Psychol. 2018;86:738-750. PMID 30138013
  37. James AC, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2015;2015:CD004690. PMID 25692403
  38. Stanley MA, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA. 2009;301:1460-7. PMID 19351943
  39. Zimmermann M, et al. Comparing the effect of two systems-level interventions on perinatal generalized anxiety disorder and posttraumatic stress disorder symptoms. Am J Obstet Gynecol MFM. 2024;6:101426. PMID 38992743